Want to see DE:AAQ1 full AI Analyst Report?
AAQ1 Stock Chart & Stats
€1.63
-€0.01(-0.61%)
At close: 4:00 PM EDT
€1.63
-€0.01(-0.61%)
Day’s Range― - ―
52-Week Range€1.26 - €2.34
Previous CloseN/A
Volume51.00
Average Volume (3M)620.00
Market Cap
€23.25M
Enterprise Value€27.65M
Total Cash (Recent Filing)€1.40M
Total Debt (Recent Filing)€984.00K
Price to Earnings (P/E)―
Beta-0.13
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding14,716,976
10 Day Avg. Volume259
30 Day Avg. Volume620
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.27
Price to Sales (P/S)1.58
P/FCF Ratio-9.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Top-line Growth & Gross MarginsRevenue improved meaningfully with very strong year-over-year growth in 2025 combined with consistently high gross profit margins. Durable unit economics give the company a structural base to improve operating leverage over time if SG&A growth is controlled, supporting long-term profitability potential.
Improved Leverage / Low DebtMaterial reduction in total debt and low debt-to-equity in 2025 reduces financial risk and interest burden, increasing strategic optionality. A stronger balance sheet supports investment in product development, regulatory approvals, or selective M&A without immediate refinancing pressure, aiding durable resilience.
Niche Implant Focus & Recurring RevenueSpecialization in orthopedic and trauma implants creates a focused, recurring revenue base tied to surgical volumes and clinical adoption. High switching costs for hospitals and surgeons and instrument/implant system integration foster durable market position and predictable demand over medium term.
Bears Say
Structural UnprofitabilityOperating and net losses have persisted across reported years, indicating the business has not yet achieved operating leverage. Persistent losses limit retained earnings, constrain reinvestment, and mean profitability depends on sustained margin improvement or cost restructuring to create lasting shareholder value.
Poor Cash GenerationConsistent negative operating and free cash flow imply ongoing cash burn and likely dependence on external financing. This structural cash-generation weakness reduces financial flexibility for R&D, regulatory filings, or commercial expansion and raises funding risk if capital markets tighten.
Negative Returns On EquityNegative ROE across reporting periods shows shareholder capital has not produced positive returns, signaling inefficiency in capital deployment. If sustained, this pressures equity value and may force dilutive financing or strategic shifts to restore returns, challenging long-term investor outcomes.
AAQ1 FAQ
What was aap Implantate AG’s price range in the past 12 months?
aap Implantate AG lowest stock price was €1.26 and its highest was €2.34 in the past 12 months.
What is aap Implantate AG’s market cap?
aap Implantate AG’s market cap is €23.25M.
When is aap Implantate AG’s upcoming earnings report date?
aap Implantate AG’s upcoming earnings report date is Aug 17, 2026 which is in 9 days.
How were aap Implantate AG’s earnings last quarter?
aap Implantate AG released its earnings results on Apr 30, 2026. The company reported -€0.116 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.116.
Is aap Implantate AG overvalued?
According to Wall Street analysts aap Implantate AG’s price is currently Overvalued.
Does aap Implantate AG pay dividends?
aap Implantate AG does not currently pay dividends.
What is aap Implantate AG’s EPS estimate?
aap Implantate AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does aap Implantate AG have?
aap Implantate AG has 14,716,976 shares outstanding.
What happened to aap Implantate AG’s price movement after its last earnings report?
aap Implantate AG reported an EPS of -€0.116 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.913%.
Which hedge fund is a major shareholder of aap Implantate AG?
Currently, no hedge funds are holding shares in DE:AAQ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
aap Implantate Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
aap Implantate AG
Operating as a medical technology firm, aap Implantate AG specializes in the development, manufacturing, and commercialization of orthopedic trauma devices. The company's market presence spans Germany, the United States, and various international regions. Its primary offerings feature LOQTEQ, an advanced anatomical plating system crucial for fracture treatment, in addition to a diverse selection of cannulated screws, conventional plates, and standard screws. Products are distributed under the 'aap' brand, reaching customers directly, including hospitals, purchasing syndicates, and hospital groups, as well as indirectly via its network of distributors. aap Implantate AG was founded in 1990 and maintains its corporate headquarters in Berlin, Germany.
Technical Analysis
Carl Zeiss Meditec
―
Eckert & Ziegler Strahlen und Medizintechnik
―
Geratherm Medical
―
MagForce AG
―
elexxion AG
―